AC Immune reports initial interim data from Phase 1b trial of ACI-24 vaccine
AC Immune announced initial interim data from an ongoing Phase 1b trial of the ACI-24 anti-Abeta vaccine to treat Alzheimer's disease like symptoms in subjects with Down syndrome as well as key takeaways from its Key Opinion Leader meeting, held in New York City. The event is being co-chaired by Professor Pfeifer and Professor William Mobley, Executive Director of the University of California San Diego's Down Syndrome Center for Research and Treatment. It features presentations from Professor Mobley and Dr. Brian Skotko, Associate Professor at Harvard Medical School and the Emma Campbell Endowed Chair on Down Syndrome and Director of the Down Syndrome Program at Massachusetts General Hospital, as well as Professor Pfeifer and Dr. Marie Kosco-Vilbois, Chief Scientific Officer of AC Immune. Highlights from Dr. Kosco-Vilbois' presentation include: The trial is a fully enrolled, placebo-controlled, 16 subjects Phase 1b study of AC Immune's ACI-24 anti-Abeta vaccine; To date, ACI-24 was well tolerated by DS subjects, demonstrating a favorable safety profile at all doses tested, mirroring previous clinical trial results; There were no subjects withdrawals from the study or serious adverse events reported, no signals of CNS inflammation or other pro-inflammatory reactions, no amyloid-related imaging abnormalities or indication of meningoencephalitis; Preliminary immunogenicity data showed an anti-Abeta IgG response that was detectable at week 4; Pending the final outcome, the Phase 2 study of ACI-24 in subjects with DS would likely focus on disease prevention and will include biomarkers and Positron Emission Tomography; imaging to monitor disease progression, in addition to quantifying anti-Abeta IgG titers generated by the vaccine.